Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.73 |
| ▸ | JAK1 | P23458 | 3/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.44 |
| ▸ | PRKX | P51817 | 1/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.42 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3532381 | 0.85 | JAK3 (1.00) | JAK3JAK1JAK2TRPA1HPGDS | |
| SCHEMBL20183342 | 0.83 | JAK3 (0.76) | JAK3JAK1JAK2TRPA1HPGDS | |
| SCHEMBL20183454 | 0.80 | JAK3 (0.52) | JAK3JAK1JAK2TRPA1ROCK1 | |
| SCHEMBL4804079 | 0.78 | JAK3 (0.44) | JAK3JAK1JAK2ROCK1ROCK2 | |
| SCHEMBL1980392 | 0.77 | JAK3 (0.74) | JAK3JAK1JAK2TRPA1HPGDS | |
| SCHEMBL17546641 | 0.76 | JAK3 (0.68) | JAK3JAK1JAK2TRPA1HPGDS | |
| SCHEMBL28345670 | 0.74 | JAK3 (0.59) | JAK3JAK1JAK2HPGDS | |
| SCHEMBL16765136 | 0.72 | HPGDS (0.74) | JAK3JAK1JAK2HPGDSIRAK4 | |
| SCHEMBL16765135 | 0.72 | HPGDS (0.74) | JAK3JAK1JAK2HPGDSIRAK4 | |
| SCHEMBL18419023 | 0.72 | HPGDS (0.74) | JAK3JAK1JAK2HPGDSIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | TEC, ABL1, LCK | JAK3 154/4885JAK1 120/4885JAK2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.